CD8B and diffuse large B-cell lymphoma: Moreover, Z-VRPR-FMK and its analog exhibit stronger inhibitory effects on the proliferation of DLBCL cells harboring a CARD11 mutation, including OCI-Ly3, than non-mutant DLBCL cells (38, 40).